Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $475.33, for a total value of $1,901,320.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $61,792.90. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

United Therapeutics stock traded up $8.57 during mid-day trading on Tuesday, hitting $485.77. 297,982 shares of the company were exchanged, compared to its average volume of 589,483. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $486.20. The company has a market capitalization of $20.92 billion, a P/E ratio of 18.41, a PEG ratio of 4.96 and a beta of 0.77. The business’s 50 day simple moving average is $441.26 and its two-hundred day simple moving average is $357.43.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same period in the prior year, the firm posted $6.39 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on UTHR shares. Oppenheimer upped their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Wells Fargo & Company boosted their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. UBS Group lifted their target price on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald increased their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

Institutional Trading of United Therapeutics

Several hedge funds have recently modified their holdings of the stock. CIBC Private Wealth Group LLC boosted its holdings in United Therapeutics by 66.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company’s stock worth $299,000 after acquiring an additional 284 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of United Therapeutics in the third quarter worth approximately $644,000. Wilmington Savings Fund Society FSB boosted its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. Center For Asset Management LLC increased its holdings in shares of United Therapeutics by 87.6% in the third quarter. Center For Asset Management LLC now owns 3,097 shares of the biotechnology company’s stock worth $1,298,000 after buying an additional 1,446 shares during the period. Finally, Captrust Financial Advisors boosted its position in United Therapeutics by 22.7% during the 3rd quarter. Captrust Financial Advisors now owns 9,437 shares of the biotechnology company’s stock valued at $3,956,000 after buying an additional 1,744 shares during the period. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.